Bulletin
Investor Alert

Market Pulse Archives

March 4, 2021, 3:04 p.m. EST

NIH to study three experimental COVID-19 treatments

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Synairgen PLC (SNG)
  • X
    AstraZeneca PLC ADR (AZN)
  • X
    AstraZeneca PLC (AZN)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

The National Institutes of Health said Thursday that it is putting three more investigational COVID-19 treatments into Phase 2/3 clinical trials. The experimental therapies are: an inhalable beta interferon developed by Synairgen's /zigman2/quotes/203511112/delayed UK:SNG -3.70% ; AstraZeneca's /zigman2/quotes/200304487/composite AZN +0.89% /zigman2/quotes/203048482/delayed UK:AZN +0.61% monoclonal antibody combination, which will be tested as an infusion and also as an injection; and Sagent Pharmaceuticals Inc.'s oral serine protease inhibitor. Sagent is privately held. The NIH said it is trying to identify and study therapies aimed at treating people who develop mild or moderate forms of COVID-19. So far during the pandemic, there are few therapies available that effectively treat patients with COVID-19. Only one, Gilead Sciences Inc.'s /zigman2/quotes/210293917/composite GILD +0.14% Veklury, has received full approval from the Food and Drug Administration, though several other companies, including Eli Lilly & Co. /zigman2/quotes/200106384/composite LLY +1.03% and Regeneron Pharmaceuticals Inc. /zigman2/quotes/203149337/composite REGN -0.25% have received emergency authorization for their antibody treatments. Over the past year, Synairgen's stock has soared 763.1%, while U.S.-listed shares of AstraZeneca are up 0.4%. The broader S&P 500 /zigman2/quotes/210599714/realtime SPX +0.77% is up 27.2%.

/zigman2/quotes/203511112/delayed
UK : U.K.: London
156.00 p
-6.00 -3.70%
Volume: 2.46M
April 9, 2021 4:35p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
£311.87 million
Rev. per Employee
N/A
loading...
/zigman2/quotes/200304487/composite
US : U.S.: Nasdaq
$ 49.94
+0.44 +0.89%
Volume: 7.43M
April 9, 2021 4:00p
P/E Ratio
40.74
Dividend Yield
2.74%
Market Cap
$131.34 billion
Rev. per Employee
$365,423
loading...
/zigman2/quotes/203048482/delayed
UK : U.K.: London
7,287.00 p
+44.00 +0.61%
Volume: 2.44M
April 9, 2021 4:35p
P/E Ratio
38.46
Dividend Yield
2.84%
Market Cap
£95.66 billion
Rev. per Employee
£282,763
loading...
/zigman2/quotes/210293917/composite
US : U.S.: Nasdaq
$ 65.11
+0.09 +0.14%
Volume: 5.85M
April 9, 2021 4:00p
P/E Ratio
833.67
Dividend Yield
4.36%
Market Cap
$81.82 billion
Rev. per Employee
$1.81M
loading...
/zigman2/quotes/200106384/composite
US : U.S.: NYSE
$ 184.49
+1.88 +1.03%
Volume: 2.61M
April 9, 2021 4:05p
P/E Ratio
27.16
Dividend Yield
1.84%
Market Cap
$176.82 billion
Rev. per Employee
$701,137
loading...
/zigman2/quotes/203149337/composite
US : U.S.: Nasdaq
$ 475.17
-1.19 -0.25%
Volume: 679,574
April 9, 2021 4:00p
P/E Ratio
15.49
Dividend Yield
N/A
Market Cap
$50.91 billion
Rev. per Employee
$931,393
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
4,128.80
+31.63 +0.77%
Volume: 1.88B
April 9, 2021 5:15p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.